With FDA approval in October of its VMS+ 3.0 system, which turns 2D echocardiograms into MRI equivalent 3D images, Ventripoint Diagnostics
(TSXV:VPT, OTCQB:VPTDF) is gearing up for a major sales and marketing program in 2020.
“Working with a strong management and clinical team over the past few months, it is clear the company is now ready to achieve its full potential as we begin selling our new system to hospitals and cardiac centers worldwide,” Justin Leushner, president and CEO, says in an interview with BioTuesdays.
Mr. Leushner joined Ventripoint as president in September 2019 and moved into the executive suite earlier this month.
He explains that VMS+ 3.0 plugs into any echocardiogram machine, the most widely used cardiac imaging technology globally, or any 2D cardiac ultrasound, such as those made by GE, Siemens, Philips and Canon.
|
|
